The Global Anti-Infectives Market Outlook to 2011 : Market Research Report

The Global Anti-Infectives Market Outlook to 2011

Published: Jun. 1, 2007 - 267 Pages

Executive Summary: Patient potential; Global market analysis; Pipeline analysis; Competitive landscape
Chapter 1 Epidemiology of Anti-infectives market: Summary; Introduction; Bacterial infections; Overview; Hepatitis; Influenza; Herpes; Tetanus, diphtheria, pertussis; Mumps, measles and rubella; Polio; Fungal infections
Chapter 2 Global market analysis: Summary; Introduction; Market analysis by country; Licensing trends; Market analysis by drug class; Leading brands dynamics; Key events in the anti-infectives market; Safety warning issued for Sanofi-Aventis’ Ketek (telithromycin); Serious adverse effects reported with the use of penicillins; Launch of new innovative class of drugs; Wyeth’s Prevnar gains from being the first vaccine to reach blockbuster status
in 2005; Increased competition within the hepatitis B market; Arrival of generic competition to market leading products in the antiinfectives’
market; Anti-virals; Leading brands of anti-viral treatments; Key brands analysis; Anti-Virals sales forecasts to 2011; Vaccines; Key brands analysis; Vaccines sales forecasts to 2011; Anti-bacterials; Market analysis by drug class; Leading brands of anti-bacterial treatments; Macrolides; Key brands analysis; Beta-lactams; Key brands analysis; Other anti-biotics; Key brand analysis; Penicillins; Market dynamics; Key brands analysis; Cephalosporins market analysis; Market dynamics; Key brands analysis; Tetracyclines market analysis; Market dynamics; Key brands analysis; Fluroquinolones; Market dynamics; Key brands analysis; Anti-bacterials sales forecasts to 2011; Anti-fungals; Market analysis by drug class; Leading brands of the anti-fungal market; Market dynamics; Key brands analysis; Anti-fungals sales forecasts to 2011; Total anti-infective market sales forecasts to 2011
Chapter 3 Pipeline analysis: Summary; Introduction; Key trends in R&D; The therapeutic area pipeline; Leading drugs in development; Profiles of key pipeline products; Phase III compounds; Albuferon (albinterferon alpha 2b); Maribavir; Ceftobiprole; Drugs in registration; Arbelic (telavancin); Zeven (dalbavancin); Mycograb (efungumab); Recently marketed drugs; Tygacil (tigecycline); Doripenem; Baraclude (entecavir); Tyzeka/Sebivo (telbivudine); Noxafil (posaconazole); Eraxis (anidulafungin); Pipeline forecasts; Factors affecting forecasts; Anti-infectives pipeline forecasts
Chapter 4 Competitive landscape: Summary; Introduction; Company market shares; GlaxoSmithKline; Pfizer; Novartis; Sanofi-Aventis; Merck; Johnson & Johnson; Roche; Wyeth; Abbott; Schering-Plough
Chapter 5 Appendix: IMS data; J1 Systemic antibiotics; J2 systemic agents for fungal infections; J3 systemic sulphonamides; J5 Antivirals for systemic use; J7 Vaccines; Index
List of Figures: Figure 2.1: Global anti-infectives market share by geography, 2005; Figure 2.2: Sales of types of anti-infectives brands, 2004-5; Figure 2.3: Competitive dynamics of the drug classes in the global anti-infectives market, 2004-5; Figure 2.4: Competitive dynamics of the drug classes in the global anti-infectives market, 2004-5; Figure 2.5: Competitive dynamics of the leading anti-viral treatments in the global anti-infectives market, 2004-5; Figure 2.6: Competitive dynamics of the leading vaccines in the global anti-infectives market, 2004-5; Figure 2.7: Competitive dynamics of the global anti-bacterial market by drug class, 2005; Figure 2.8: Competitive dynamics of the ten leading brands in the anti-bacterial drug class, 2005; Figure 2.9: Competitive dynamics of the ten leading brands in the anti-fungal drug class, 2005; Figure 3.10: Prevailing R&D approaches, 2006; Figure 3.11: The anti-infectives pipeline by indication and stage of development, 2006; Figure 3.12: Leading recently launched products and late-stage R&D in the anti-infectives market, 2005; Figure 4.13: Competitive dynamics of the leading players in the global anti-infectives market, 2005; Figure 4.14: GSK’s anti-infectives sales, 2005; Figure 4.15: Pfizer’s anti-infectives sales, 2005; Figure 4.16: Novartis’ anti-infectives sales, 2005; Figure 4.17: Sanofi-Aventis’ anti-infectives sales, 2005; Figure 4.18: Merck’s anti-infectives sales, 2005; Figure 4.19: Johnson & Johnson anti-infectives sales, 2005; Figure 4.20: Roche’s anti-infectives sales, 2005; Figure 4.21: Wyeth’s anti-infectives sales, 2005; Figure 4.22: Abbott’s anti-infectives sales, 2005; Figure 4.23: Schering-Plough’s anti-infectives sales, 2005
List of Tables: Table 1.1: Estimated prevalence of infective diseases across seven major pharmaceutical markets, 2005; Table 1.2: Estimated incidence of community acquired pneumonia infections across seven major markets, 2005; Table 1.3: Estimated incidence of uRTIs caused by streptococcus infection across seven major markets, 2005; Table 1.4: Estimated incidence of community acquired urinary tract infections across seven major markets, 2005; Table 1.5: Estimated incidence of bacterial skin and skin structure infections across seven major markets, 2005; Table 1.6: Forecast epidemiology of CAP across the seven major markets, 2005-11; Table 1.7: Forecast epidemiology of uRTIs caused by streptococcus infection across the seven major markets, 2005-11; Table 1.8: Forecast epidemiology of urinary tract infections across the seven major markets, 2005-11; Table 1.9: Forecast epidemiology of skin and skin structure infections across the seven major
markets, 2005-11; Table 1.10: Estimated prevalence of HBV and HCV across the seven major markets, 2005; Table 1.11: Forecast epidemiology of HBV and HCV across the seven major markets, 2005-11; Table 1.12: Estimated prevalence of influenza across the seven major markets, 2005; Table 1.13: Estimated seroprevalence of HSV-1 and HSV-2 across the seven major markets, 2005; Table 1.14: Forecast seroprevalence of HSV-1 and HSV-2 across the seven major markets, 2005-
11; Table 1.15: Estimated vaccine coverage and incidence of DPT across the seven major markets,
2005; Table 1.16: Estimated vaccine coverage and incidence of MMR across the seven major markets,
2005; Table 1.17: Estimated vaccine coverage and incidence of polio across the seven major markets,
2005; Table 1.18: Estimated incidence of systemic fungal infections in across seven major markets, 2005; Table 1.19: Forecast epidemiology of systemic fungal infections across the seven major markets,
2005-11; Table 2.20: Breakdown of the global Anti-infective market by drug class, 2001-05; Table 2.21: Leading brands in the global Anti-infectives market, 2004-05; Table 2.22: Breakdown of the global anti-viral market by drug class, 2001-05; Table 2.23: Leading anti-virals in the global anti-infectives market,; Table 2.24: Anti-virals sales forecast, 2005-11; Table 2.25: Leading vaccines in the global anti-infectives market,; Table 2.26: Vaccines sales forecast, 2005-11; Table 2.27: Breakdown of the global anti-bacterial market by drug class, 2001-05; Table 2.28: Leading Anti-bacterials in the global anti-infectives market,; Table 2.29: Leading macrolides in the global anti-infectives market,; Table 2.30: Overview of Pfizer’s Zithromax franchise; Table 2.31: Leading ‘other’ beta-lactams in the global anti-infectives market,; Table 2.32: Leading ‘other’ anti-biotics in the global anti-infectives market,; Table 2.33: Leading penicillins in the global anti-infectives market,; Table 2.34: Leading cephalosporin brands in the global anti-bacterials market, 2004-05; Table 2.35: Leading tetracycline brands in the global anti-bacterials market, 2004-05; Table 2.36: Leading fluoroquinolones brands in the global anti-infectives market, 2004-5; Table 2.37: Anti-bacterials’ sales forecast, 2005-11; Table 2.38: Anti-bacterials’ sales forecast, 2005-11; Table 2.39: Anti-bacterials’ sales forecast, 2005-11; Table 2.40: The global anti-fungal market by drug class, 2001-05; Table 2.41: Leading anti-fungals brands in the global anti-infectives market, 2004-5; Table 2.42: Anti-fungal sales forecast, 2005-11; Table 2.43: Therapeutic sales forecasts by drug class, 2005-11; Table 3.44: Anti-infectives pipeline forecasts, 2006-11; Table 4.45: Leading players in the global anti-infectives market, 2004-5; Table 4.46: GSK’s anti-infectives product portfolio, 2004-5; Table 4.47: GSK’s anti-infectives R&D product pipeline, 2006; Table 4.48: Pfizer’s anti-infectives product portfolio, 2004-5; Table 4.49: Pfizer’s anti-infectives R&D product pipeline, 2006; Table 4.50: Novartis’ anti-infectives product portfolio, 2004-5; Table 4.51: Novartis’ anti-infectives R&D product pipeline, 2006; Table 4.52: Sanofi-Aventis’ anti-infectives product portfolio, 2004-5; Table 4.53: Sanofi-Aventis anti-infectives R&D product pipeline, 2006; Table 4.54: Merck’s anti-infectives product portfolio, 2004-5; Table 4.55: Merck’s anti-infectives R&D product pipeline, 2006; Table 4.56: Johnson & Johnson anti-infectives product portfolio, 2004-5; Table 4.57: Johnson & Johnson’s anti-infectives R&D product pipeline, 2006; Table 4.58: Roche’s anti-infectives product portfolio, 2004-5; Table 4.59: Roche’s anti-infectives R&D product pipeline, 2006; Table 4.60: Wyeth’s anti-infectives product portfolio, 2004-5; Table 4.61: Wyeth’s anti-infectives R&D product pipeline, 2006; Table 4.62: Abbott’s anti-infectives product portfolio, 2004-5; Table 4.63: Abbott’s anti-infectives R&D product pipeline, 2006; Table 4.64: Schering-Plough’s anti-infectives product portfolio, 2004-5; Table 4.65: Schering-Plough’s anti-infectives R&D product pipeline, 2006

Abstract

The Global Anti-infectives Market Outlook to 2011 The anti-infectives market is forecast to expand at a CAGR of 4.8% over the period 2005-11, riven largely by gains in the anti-bacterial and anti-viral classes. This represents significant market opportunity for pharma companies to expand their sales potential by targeting high growth markets. The Global Anti-infectives Market Outlook to 2011 provides comprehensive coverage of the anti-infectives market, incorporating a detailed epidemiological analysis of the major indications and the key factors impacting their prevalence. Analysis of the major brands and profiles of the leading pharmaceutical companies will ensure that you can plan effectively, evaluate key changes in the competitive landscape, and identify potential growth areas within the global anti-infectives market. Use this report to assess anti-infective therapies that will be crucial to maintaining positive sales growth, analyze the marketed product portfolio and R&D pipelines of the leading 10 pharmaceutical companies in the global anti-infectives market.

Key findings of the report...

The anti-infectives market is forecast to expand at a CAGR of 4.8% over the period 2005-11. Growth is forecast to be driven by gains in the anti-bacterial and anti-viral classes, with anti-bacterials expanding at a low rate, due to the sheer size of the class.
Anti-bacterials occupied the leading position in the anti-infectives market in 2005 with a market share of 59.9% and $33,919m in sales for the same year. The major growth driver in this drug class are the macrolides and the beta-lactams drug classes which together reported combined sales of $7,963m or some 23.5% of total anti-bacterial sales.
Anti-fungals was the only drug class to record negative growth in 2004-5 reported at -4.4% having witnessed a decline of $207m from 2004 sales of $4,646m to $4,439m in 2005. This decrease in sales growth has been attributed to the low levels of product proliferation and innovation in this drug class.
With limited levels of new product introductions, particularly within the anti-fungal and anti-bacterial drug classes, generic competition is a major factor shaping the anti-infectives market, which saw sales of generic products increase by 15.8% in 2005 to $21.0bn from $18.1bn in the previous year.

Key questions answered in this report

What will be the major growth indications in the anti-infectives area over the period 2006-11?
What are the current trends within the major therapy areas of anti-fungals, anti-bacterials, anti-virals and vaccines across the seven major markets?
How have recent launches from companies such as GSK, BMS, J&J, Roche and Wyeth performed?
What are the most exciting compounds currently in development for anti-infectives indications, and what is the forecast market potential of these products?
How significant is the threat of generics to the overall performance of the global anti-infectives market?
Which companies are best positioned to succeed in the global anti-infectives market over the period 2006-11?

Top five reasons to order your copy today

Quantify patient potential, assess treatment trends and sales patterns across the 5 major anti-infective indications, the US, Japanese and top EU5 markets and the 10 leading companies.
Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of anti-infective treatments including anti-virals, anti-bacterials, anti-fungals and vaccines.
Evaluate how market share of leading companies, such as GSK, Pfizer, Abbott, BMS and Wyeth will change over the next 6 years and position yourself for success.
Benchmark forecast perfomance of the leading players by using analysis of key products in major indications over the period 2006 to 2011.
Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

The Global Anti-Infectives Market Outlook to 2011

Table of Contents

Abstract